SeekingAlpha · Aug 25, 2026
Inovio: The Final Countdown To A Binary FDA Decision
Inovio Pharmaceuticals is a single-asset, late-stage biotech, with value hinging on the October 30th PDUFA decision for INO-3107. Learn why INO stock is a hold.
IN
NASDAQ · INO
Inovio Pharmaceuticals, Inc.
Healthcare · Biotechnology
$1.27
Up+$0.06 (+4.72%)
Updated Sep 1, 2026, 8:10 PM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 114.68M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- $0.56 – $2.98
- Volume
- 5.63M
- Avg. volume
- 1.16M
Price performance
INO price history
1M range · 21 trading sessions · Daily adjusted prices
INO closed at $1.27 after 21 trading sessions, up 82.26% for the selected period.
- Last close
- $1.27
- Period change
- +82.26%
- Period low
- $0.66
- Period high
- $1.30
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $1.30 | $1.37 | $1.26 | $1.27 | 5.63M |
| Aug 28, 2026 | $1.27 | $1.32 | $1.255 | $1.29 | 1.7M |
| Aug 27, 2026 | $1.29 | $1.31 | $1.25 | $1.26 | 2.31M |
| Aug 26, 2026 | $1.28 | $1.3699 | $1.245 | $1.30 | 3.72M |
| Aug 25, 2026 | $1.25 | $1.30 | $1.235 | $1.29 | 3.6M |
| Aug 24, 2026 | $1.19 | $1.30 | $1.15 | $1.25 | 4.59M |
| Aug 21, 2026 | $1.225 | $1.241 | $1.15 | $1.18 | 5.02M |
| Aug 20, 2026 | $1.30 | $1.30 | $1.20 | $1.21 | 4.14M |
| Aug 19, 2026 | $1.22 | $1.3191 | $1.145 | $1.30 | 6.97M |
| Aug 18, 2026 | $1.14 | $1.22 | $1.0701 | $1.20 | 4.75M |
| Aug 17, 2026 | $1.07 | $1.15 | $1.04 | $1.15 | 6.49M |
| Aug 14, 2026 | $0.9295 | $1.10 | $0.8978 | $1.09 | 12.21M |
| Aug 13, 2026 | $0.81 | $0.9624 | $0.7964 | $0.9001 | 12.86M |
| Aug 12, 2026 | $0.7606 | $0.78 | $0.747 | $0.77 | 3.14M |
| Aug 11, 2026 | $0.7814 | $0.81 | $0.7602 | $0.7658 | 4.42M |
| Aug 10, 2026 | $0.66 | $0.7524 | $0.6596 | $0.7364 | 3.32M |
| Aug 7, 2026 | $0.6732 | $0.6845 | $0.641 | $0.668 | 3.05M |
| Aug 6, 2026 | $0.6738 | $0.6849 | $0.66 | $0.6738 | 1.73M |
| Aug 5, 2026 | $0.6711 | $0.6899 | $0.661 | $0.677 | 2.29M |
| Aug 4, 2026 | $0.7064 | $0.7198 | $0.6451 | $0.6631 | 3.99M |
| Aug 3, 2026 | $0.69 | $0.7238 | $0.68 | $0.6968 | 7.63M |
Latest INO news
The latest Smart Investors Daily articles mentioning INO.
Stock researchCompany · Overview
INO research
Overview
Company profile and research snapshot.
Company profile
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $6.00
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Jefferies | Buy | — |
| Aug 3, 2026 | Piper Sandler | Overweight | — |
| Jun 1, 2026 | HC Wainwright & Co. | Neutral | — |
| Nov 14, 2025 | Piper Sandler | Overweight | — |
| Aug 14, 2025 | HC Wainwright & Co. | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Jefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3
Jefferies analyst Roger Song upgrades Inovio Pharmaceuticals (NASDAQ:INO) from Hold to Buy and raises the price target from $1.8 to $3.
Yahoo · Aug 13, 2026
Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ...
Inovio reports a narrowed net loss and strong progress toward a potential INO-3107 launch, while securing funding through late Q1 2027.
Yahoo · Aug 13, 2026
Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby summary of Inovio Pharmaceuticals, Inc.'s Q2 2026 earnings call
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
